Acquisition of Fusion completed
05 June 2024 Acquisition of Fusion completed AstraZeneca today announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. This acquisition complements AstraZeneca's leading oncology portfolio with the addition of the Fusion